Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others.
She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University.
She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
Philips recently announced two new capabilities of its echocardiogram system, the EPIQ CVx cardiology ultrasound platform, that will assist in heart imaging and functional studies, improving the accuracy and duplication ... Read more
Owlstone Medical has established a strategic collaboration with Actelion Pharmaceuticals to develop and validate a breath-based diagnostic test for different types of pulmonary hypertension (PH). Actelion Pharmaceuticals will solely fund this ... Read more
Teva Pharmaceutical Industries launched a generic version of Letairis (ambrisentan) in the United States for the treatment of pulmonary arterial hypertension. Generic ambrisentan will be available as 5 and ... Read more
Treatment with Revatio (sildenafil) after surgery to the heart’s mitral valve significantly lowered pulmonary arterial pressure in patients with pre-operative significant pulmonary hypertension, researchers from Israel report. The study, “Sildenafil ... Read more
An updated guideline with new recommendations for the treatment of patients with pulmonary arterial hypertension (PAH) was released by the American College of Chest Physicians (CHEST). The free guide, titled “Therapy ... Read more
Eligible pulmonary hypertension patients could gain access to financial assistance in paying for PH therapies approved by the U.S. Food and Drug Administration (FDA) under a newly opened copay assistance program set ... Read more
A ventilator-compatible nitric oxide generator and delivery system, called AirNOvent, for patients with pulmonary hypertension and related conditions, will be made available by Circassia Pharmaceuticals to hospitals in the U.S. ... Read more
The prevalence of pulmonary arterial hypertension (PAH) in South Korea is comparable with that reported in other countries, according to a reassessment study of medical insurance data. The study, ... Read more
The Stanford University School of Medicine is the first clinical site for a Phase 2 trial testing levosimendan as a potential treatment for pulmonary hypertension associated with heart failure and ... Read more
Transgelin, a smooth muscle protein, is abundant in patients with irreversible pulmonary arterial hypertension (PAH) secondary to congenital heart disease and may contribute to PAH progression, a study reports. The study, ... Read more